These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 29655904)

  • 1. 3D printed, controlled release, tritherapeutic tablet matrix for advanced anti-HIV-1 drug delivery.
    Siyawamwaya M; du Toit LC; Kumar P; Choonara YE; Kondiah PPPD; Pillay V
    Eur J Pharm Biopharm; 2019 May; 138():99-110. PubMed ID: 29655904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment.
    Wilkins EL; Cohen CJ; Trottier B; Esser S; Smith DE; Haas B; Brinson C; Garner W; Chuck S; Thorpe D; De-Oertel S
    AIDS Care; 2016; 28(3):401-8. PubMed ID: 26489045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens.
    Mills AM; Cohen C; Dejesus E; Brinson C; Williams S; Yale KL; Ramanathan S; Wang MH; White K; Chuck SK; Cheng AK
    HIV Clin Trials; 2013; 14(5):216-23. PubMed ID: 24144898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF.
    Hodder SL; Mounzer K; Dejesus E; Ebrahimi R; Grimm K; Esker S; Ecker J; Farajallah A; Flaherty JF;
    AIDS Patient Care STDS; 2010 Feb; 24(2):87-96. PubMed ID: 20156091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults: week 96 efficacy and safety from a randomized phase 3b study.
    van Lunzen J; Antinori A; Cohen CJ; Arribas JR; Wohl DA; Rieger A; Rachlis A; Bloch M; Segal-Maurer S; Garner W; Porter D; Bosse M; Piontkowsky D; Chuck SK; De-Oertel S
    AIDS; 2016 Jan; 30(2):251-9. PubMed ID: 26684822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects.
    Porter DP; Kulkarni R; Fralich T; Miller MD; White KL
    HIV Clin Trials; 2015; 16(1):30-8. PubMed ID: 25777187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic review of renal and bone safety of the antiretroviral regimen efavirenz, emtricitabine, and tenofovir disoproxil fumarate in patients with HIV infection.
    Bedimo R; Rosenblatt L; Myers J
    HIV Clin Trials; 2016 Nov; 17(6):246-266. PubMed ID: 27809711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Day-On, Day-Off emtricitabine, tenofovir disoproxil fumarate and efavirenz single tablet regimen (DODO) as maintenance therapy in HIV-infected patients.
    Costantini A; Tontini C; Rocchi M; Martini M; Butini L
    Infez Med; 2018 Jun; 26(2):126-132. PubMed ID: 29932084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults.
    Cohen C; Wohl D; Arribas JR; Henry K; Van Lunzen J; Bloch M; Towner W; Wilkins E; Ebrahimi R; Porter D; White K; Walker I; Chuck S; De-Oertel S; Fralich T
    AIDS; 2014 Apr; 28(7):989-97. PubMed ID: 24508782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine/tenofovir DF: pooled 96-week data from ECHO and THRIVE Studies.
    Nelson MR; Elion RA; Cohen CJ; Mills A; Hodder SL; Segal-Maurer S; Bloch M; Garner W; Guyer B; Williams S; Chuck S; Vanveggel S; Deckx H; Stevens M
    HIV Clin Trials; 2013; 14(3):81-91. PubMed ID: 23835510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of coformulated efavirenz/emtricitabine/tenofovir single-tablet regimen in treatment-naive patients infected with HIV-1.
    Gallien S; Flandre P; Nguyen N; De Castro N; Molina JM; Delaugerre C
    J Med Virol; 2015 Feb; 87(2):187-91. PubMed ID: 25070158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stable Caloric Intake and Continued Virologic Suppression for HIV-Positive Antiretroviral Treatment-Experienced Women After Switching to a Single-Tablet Regimen of Emtricitabine, Rilpivirine, and Tenofovir Disoproxil Fumarate.
    Menezes P; Mollan K; Hoffman E; Xie Z; Wills J; Marcus C; Rublein J; Hudgens M; Eron JJ
    AIDS Res Hum Retroviruses; 2018 Jun; 34(6):481-485. PubMed ID: 29607652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of DTG + ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States.
    Peng S; Tafazzoli A; Dorman E; Rosenblatt L; Villasis-Keever A; Sorensen S
    J Med Econ; 2015; 18(10):763-76. PubMed ID: 25934146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacokinetics, pharmacodynamics, and clinical role of fixed dose combination of tenofovir disoproxil fumarate, lamivudine and reduced dose efavirenz (TLE-400) in treating HIV-1 infection.
    Dubrocq G; Rakhmanina N
    Expert Opin Drug Metab Toxicol; 2018 Aug; 14(8):773-779. PubMed ID: 29985071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials.
    Hagins D; Orkin C; Daar ES; Mills A; Brinson C; DeJesus E; Post FA; Morales-Ramirez J; Thompson M; Osiyemi O; Rashbaum B; Stellbrink HJ; Martorell C; Liu H; Liu YP; Porter D; Collins SE; SenGupta D; Das M
    HIV Med; 2018 Nov; 19(10):724-733. PubMed ID: 30101539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial.
    Vincent KL; Moss JA; Marzinke MA; Hendrix CW; Anton PA; Pyles RB; Guthrie KM; Dawson L; Olive TJ; Butkyavichene I; Churchman SA; Cortez JM; Fanter R; Gunawardana M; Miller CS; Yang F; Rosen RK; Vargas SE; Baum MM
    PLoS Med; 2018 Sep; 15(9):e1002655. PubMed ID: 30265679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacological properties and clinical findings of new drugs for the treatment of HIV-1, FTC/TAF 200/10 and 200/25 mg (Descovy
    Nakamoto H; Yamada H; Watanabe Y
    Nihon Yakurigaku Zasshi; 2017; 150(5):251-260. PubMed ID: 29118289
    [No Abstract]   [Full Text] [Related]  

  • 18. Fixed dose darunavir boosted with cobicistat combined with emtricitabine and tenofovir alafenamide fumarate.
    Cevik M; Orkin C
    Curr Opin HIV AIDS; 2018 Jul; 13(4):315-319. PubMed ID: 29528852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-World Assessment of Renal and Bone Safety among Patients with HIV Infection Exposed to Tenofovir Disoproxil Fumarate-Containing Single-Tablet Regimens.
    Nkhoma ET; Rosenblatt L; Myers J; Villasis-Keever A; Coumbis J
    PLoS One; 2016; 11(12):e0166982. PubMed ID: 27941989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. WITHDRAWN. Effectiveness and safety of first-line tenofovir + emtricitabine + efavirenz for patients with HIV.
    Omeje I; Okwundu CI
    Cochrane Database Syst Rev; 2012 Feb; (2):CD007276. PubMed ID: 22336829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.